Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
24 studies found for:    HIV vaccine and NIAID | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
HIV vaccine and NIAID | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers
Conditions: Healthy Volunteer;   HIV Vaccine
Interventions: Biological: Ad4-mgag;   Biological: Ad4-EnvC150
2 Recruiting Safety and Immune Response to a Clade C DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Protein/MF59 vaccine;   Biological: Placebo
3 Recruiting Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent Subtype C gp120/MF59;   Biological: Placebo
4 Recruiting A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.
Condition: HIV Infections
Intervention: Biological: rAAV1-PG9DP
5 Recruiting Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
Condition: HIV Infections
Interventions: Biological: MVA/HIV62B vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo
6 Recruiting Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Bivalent Subtype C gp120/MF59 vaccine;   Biological: Bivalent Subtype C gp120/AS01B vaccine;   Biological: Placebo
7 Recruiting Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses
Conditions: HIV;   Pneumococcal Infections;   Pneumococcal Vaccines
Interventions: Biological: PCV-13;   Biological: PPSV-23
8 Recruiting Safety and Virologic Effect of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults
Condition: HIV-1
Intervention: Biological: VRC-HIVMAB080-00-AB (VRC01LS)
9 Recruiting Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali
Condition: Malaria
Interventions: Biological: Pfs25M-EPA/AS01;   Biological: Pfs230D1M-EPA/AS01;   Other: AS01;   Biological: Bexsero (Comparator Vaccine);   Biological: Fluarix;   Other: Normal Saline;   Drug: Coartem
10 Recruiting PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
Condition: Ebola Virus Disease
Intervention:
11 Recruiting Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults
Conditions: Prevention of HIV Infection;   HIV Antibodies;   Monoclonal Antibody, Human;   Neutralizing Antibody
Interventions: Biological: VRC-HIVMAB080-00-AB (VRC01LS);   Biological: VRC-HIVMAB060-00-AB (VRC01)
12 Recruiting Perturbing of HIV Reservoir With Immune Stimulation
Conditions: AIDS;   HIV
Interventions: Biological: Fluarix;   Biological: Pneumovax;   Other: Placebo
13 Recruiting VRC 605: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
Condition: HIV Prevention
Intervention: Biological: VRC-HIVMAB075-00-AB
14 Recruiting Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies
Condition: Blood Component Removal
Intervention:
15 Recruiting Causes of Rotavirus Vaccine Failure in Zambian Children
Condition: Diarrhoea
Intervention:
16 Recruiting Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: VRC01LS
17 Recruiting Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection
Condition: HIV-1 Infection
Interventions: Drug: Vorinostat;   Biological: AGS-004
18 Recruiting Screening Volunteers for Influenza Challenge Studies
Condition: Influenza, Human
Intervention:
19 Not yet recruiting Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®-or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent subtype C gp120/MF59;   Biological: Bivalent subtype C gp120/AS01(B);   Biological: Placebo
20 Recruiting Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Trial to Determine Safety and Development of Protective Efficacy After Exposure to Only Pre-erythrocytic Stages of Plasmodium Falciparum
Condition: Malaria
Interventions: Drug: Chloroquine Phosphate;   Drug: Pyrimethamine;   Biological: Sanaria PfSPZ Challenge

   Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.